MD

Business Context and Reporting Period

Company: Pediatrix Medical Group, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: Pediatrix is the nation's largest health care services company focused on physician services for newborn, maternal-fetal, and other pediatric subspecialty care. The company operates a national network of approximately 834 affiliated physicians, including 644 neonatologists, providing care in 32 states and Puerto Rico. Services include neonatal intensive care unit (NICU) management, maternal-fetal medicine, pediatric cardiology, and newborn screening (hearing and metabolic).

Key Financial Metrics

Note: The company repaid its entire $54 million line of credit balance during 2005.

Material Changes vs. Prior Period

• Revenue Growth: Net patient service revenue increased 12.0% ($74.1 million) to $693.7 million. This was driven by $41.1 million from acquisitions (13 physician groups) and $33.0 million from same-unit growth (increased NICU patient days and volume in cardiology/screening).
• Profitability Decline: Net income decreased 9.4% to $89.0 million. Operating income fell 5.5% to $147.7 million.
• Expense Increases: General and administrative expenses surged 45.1% to $115.3 million. This increase was primarily due to a $20.9 million increase in reserves for government investigations and $8.0 million in new equity-based compensation expenses (restricted stock).
• Payor Mix Shift: The government component of gross patient service revenue increased to 54% (from 52% in 2004), resulting in lower average reimbursement rates and higher contractual adjustments.
• Liquidity Position: The company moved from a working capital surplus of $21.2 million in 2004 to a deficit of $2.2 million in 2005, largely due to the accrual of the settlement reserve and accrued salaries/bonuses.

Guidance, Outlook, Risks, and Contingencies

• Government Investigations (Critical Contingency): On February 8, 2006, the company announced an agreement in principle to settle federal and state investigations regarding Medicaid and TRICARE billing practices. Reserves were increased to $25.1 million. The settlement is subject to final negotiation and approval, including a corporate integrity agreement.
• Antitrust Investigation: The Federal Trade Commission (FTC) continues an active investigation into the company's 2001 acquisition of Magella Healthcare and general business practices. The outcome remains uncertain.
• Acquisition Strategy: Management plans to invest $90 million to $100 million in acquisitions during 2006. The company is also exploring opportunities in anesthesiology.
• Equity Compensation: The company adopted FAS 123R effective January 1, 2006, which will require expensing stock options. This is expected to impact 2006 results by approximately $2.5 million.
• Stock Repurchases: The company completed a $50 million share repurchase program in late 2005. No additional programs were approved for 2006 at the time of filing.

Investor Verification Checklist

• Settlement Finalization: Verify the final terms and total cost of the Medicaid/TRICARE settlement, including any non-financial corporate integrity agreement requirements.
• FTC Investigation Status: Monitor updates on the FTC antitrust investigation regarding the Magella acquisition and potential divestiture or penalties.
• Payor Mix Trends: Assess the impact of the increasing percentage of government-sponsored patients (Medicaid) on future reimbursement rates and margins.
• Acquisition Integration: Review the financial performance of the 13 physician groups acquired in 2005 to ensure they meet projected revenue and profitability targets.
• Insurance Renewals: Confirm the renewal of professional liability insurance coverage (expiring May 1, 2006) and any changes to deductibles or premiums.